GT
KRTX

Glenmede Trust’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Glenmede Trust’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,689
Closed -$307K – 1383
2023
Q2 		$307K Hold
1,689
– – ﹤0.01% 985
2023
Q1 		$307K Sell
1,689
-653
-28% -$125K ﹤0.01% 990
2022
Q4 		$460K Buy
2,342
+292
+14% +$62.6K ﹤0.01% 853
2022
Q3 		$461K Sell
2,050
-648
-24% -$131K ﹤0.01% 838
2022
Q2 		$341K Buy
+2,698
New +$310K ﹤0.01% 967
2021
Q1 		– Sell
-2,590
Closed -$263K – 1273
2020
Q4 		$263K Sell
2,590
-1,130
-30% -$105K ﹤0.01% 1000
2020
Q3 		$287K Buy
3,720
+935
+34% +$79.7K ﹤0.01% 935
2020
Q2 		$310K Buy
2,785
+595
+27% +$51.7K ﹤0.01% 896
2020
Q1 		$164K Hold
2,190
– – ﹤0.01% 1261
2019
Q4 		$164K Buy
+2,190
New +$95.9K ﹤0.01% 1261

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Glenmede Trust's KRTX Position: Q3 2023 in Review

Glenmede Trust sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 1,689 shares — an estimated $307K sold.

Glenmede Trust first reported a position in KRTX in Q4 2019 and held it in 10 quarters. The position peaked at $461K in Q3 2022. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Glenmede Trust reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Glenmede Trust sold 1,689 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $307K.
  • Glenmede Trust first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
  • Glenmede Trust's Karuna Therapeutics, Inc. Common Stock position peaked at $461K in Q3 2022.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Glenmede Trust's 13F filing for Q3 2023, filed 14 Nov 2023.